What Desirel Treats: Main Uses and Benefits

Desirel is a medication commonly used to provide multifaceted symptomatic support across three key therapeutic domains, focusing on emotional balance, sleep health, and the management of associated agitation. Its core indication is the treatment of Major Depressive Disorder, and it is also applied in addressing co-occurring sleep and anxiety symptoms.

Therapeutic applications generally include the symptomatic management of Major Depressive Disorder, addressing symptoms of restlessness and anxiety that often accompany mood disorders, and providing symptomatic support for sleep disturbances that interfere with daily stability.

Symptomatic Support for Complex Needs

This medication is generally applied in contexts where a patient's symptom profile includes both low mood and heightened restlessness. This is considered relevant in clinical settings marked by the heightened distress of insomnia and agitation, such as in certain presentations in older adults. It supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.

Quick Fact: Symptomatic Support for Sleep and Agitation

Desirel is frequently used to address significant neurovegetative sleep disturbances, particularly difficulty falling asleep and problems maintaining sleep. The medication is commonly used to help with a calming effect that may assist with easing these distressing manifestations and supports general well-being.

Regulatory References

1. NIH StatPearls clinical overview

Official Regulatory Eligibility for Desirel (Trazodone)

Official regulatory documents define strict criteria for who is eligible to use Trazodone Hydrochloride (Desirel) and who must be excluded. Use is primarily established for adults aged 18 years and older.

Classification	Population Status	Regulatory Basis (Example)
Contraindicated	Patients taking or who have stopped an MAOI (e.g., Linezolid) within 14 days	FDA Label, EMA SmPC
Contraindicated	Individuals in the acute recovery phase following a Myocardial Infarction (MI)	FDA Label
Not Established	Pediatric patients (under 18 years); safety and efficacy are not established	FDA Label
Caution/Restricted	Older adults (ge 65 years); requires close monitoring	FDA Label, EMA SmPC

Condition-Specific Limitations:

• Organ Function: Use requires caution in patients with documented severe hepatic (liver) or renal (kidney) impairment, as Trazodone has not been adequately studied in these populations.
• Cardiovascular Conditions: Patients with pre-existing cardiac disease, such as conduction defects or angina pectoris, require close monitoring and caution during use.
• Reproductive Status: The medicine is not recommended for use in the third trimester of pregnancy due to the risk of neonatal symptoms. Use during lactation (breastfeeding) is subject to a regulatory caution statement, as the drug is excreted in human milk.

These classifications, mandated by regulatory authorities, determine who is absolutely prohibited from use and who requires special consideration based on age, existing conditions, or physiological status.

Interactions with other medicines and products

The official regulatory profile for Desirel (Trazodone) details specific interaction patterns classified as pharmacokinetic (PK) and pharmacodynamic (PD) effects, all derived from authoritative government sources.

Prohibited Combinations and Timing Rules

The co-administration of Trazodone with Monoamine Oxidase Inhibitors (MAOIs), including agents like Linezolid, is formally contraindicated due to the severe risk of Serotonin Syndrome. A mandatory 14-day separation period must elapse between discontinuing an MAOI and initiating Trazodone treatment, and conversely.

Metabolic and Exposure Interactions

Trazodone's clearance is governed by the CYP3A4 enzyme system. Co-administration with potent CYP3A4 inhibitors (such as ritonavir or ketoconazole) can substantially increase Trazodone plasma concentrations, requiring dosage monitoring. Conversely, CYP3A4 inducers (such as carbamazepine) may significantly decrease Trazodone exposure. Trazodone may also affect the plasma levels of co-administered drugs; for instance, monitoring is required for Digoxin and Phenytoin due to potential increases in their serum levels.

Pharmacodynamic Interactions

Due to its mechanism, Trazodone contributes to additive risks with other agents. The combination with other serotonergic drugs increases the documented risk of Serotonin Syndrome. Trazodone may enhance the effects of other CNS depressants, including alcohol. Furthermore, co-administration with drugs known to prolong the QT interval should be avoided. The use with anticoagulants (like Warfarin) and NSAIDs increases the officially documented risk of abnormal bleeding.

Dual Modulation of Serotonin Signaling

Desirel exerts its primary action within the Central Nervous System (CNS) by modulating the serotonergic system. The drug functions as a dual agent: it acts as an inhibitor of the Serotonin Transporter (SERT), increasing the concentration of serotonin in the synaptic cleft, while simultaneously acting as an antagonist (blocker) at specific 5-HT2A receptors. This concurrent action alters the dynamics of serotonin signaling and contributes to a regulated state of neurotransmitter activity.

Influence on Alertness and Excitatory Pathways

Beyond serotonin, the drug is also a potent antagonist at alpha1-adrenergic and histamine H1 receptors. These targets are intrinsically involved in promoting neural excitation and wakefulness signals. By blocking these secondary receptors, the drug reduces the transmission of excitatory and alerting signals across neural pathways. The integrated cascade of multi-receptor antagonism results in the physiological consequence of reduced neural excitability and modulated wakefulness, forming the basis of the drug's effect profile.

Official Administration Guidelines (Oral)

Desirel (trazodone hydrochloride) is an oral tablet for which administration must follow specific instructions concerning dosage, timing, and preparation to ensure correct use.

Dosing and Regimen

The recommended initial dose is 150 mg per day, administered in divided doses. The dosage may be gradually increased by 50 mg/day every three to four days based on response. For most outpatients, the maximum dose generally does not exceed 400 mg/day in divided doses. In more severely ill patients (inpatients), the dose may be given up to, but not in excess of, 600 mg/day in divided doses. After an adequate response is reached, the dosage may be gradually reduced to the lowest effective level.

Timing and Preparation

This medication must be taken shortly after a meal or light snack. This instruction is given to minimize the risk of lightheadedness, dizziness, and stomach upset. If drowsiness occurs, the largest portion of the total daily dose may be administered at bedtime. Tablets are scored and may be swallowed whole or broken along the score line to obtain half-tablet dosages, but they must not be crushed or chewed.

Special Conditions

• Discontinuation: The dosage should be gradually reduced when discontinuing the medicine, rather than stopping abruptly, to minimize potential discontinuation-related effects.
• MAOI Washout: A minimum of 14 days must elapse between discontinuing a Monoamine Oxidase Inhibitor (MAOI) antidepressant and initiating Desirel, and vice-versa.
• Pediatric Use: The safety and efficacy of this medicine have not been established in pediatric patients, and it is not approved for use in this population.

Research Evidence / Overview of Studies for Desirel

Research Evidence for Major Depressive Disorder (MDD)

The research base for the study compound's evaluation in Major Depressive Disorder (MDD) is primarily composed of randomized controlled trials (RCTs). These studies were typically short-term, lasting between six and twelve weeks, and examined the compound against an inactive placebo in adult populations. Researchers primarily monitored changes using standardized rating scales relevant to depression. Findings described patterns observed in the evolution of core depressive symptoms in the studied populations.

Research Evidence for Symptomatic Support for Sleep Disturbances

The study compound was studied for its characteristics related to sleep disturbances, an area often explored in conjunction with depression. Research includes pilot-scale RCTs that examined outcomes related to systemic imbalance associated with poor sleep. Findings described patterns related to measurements in both objective sleep metrics (like Polysomnography) and subjective patient-reported outcomes. However, certainty remains low regarding the sustained, long-term profile for isolated sleep disturbances, as evidence quality varies across studies.

Research Evidence for Restlessness and Agitation

The research exploring restlessness and agitation often includes studies where these were secondary outcomes. This work was evaluated in complex settings, such as older adults with certain underlying health conditions, where symptoms vary in intensity. Studies monitored acute changes in agitation and irritability using sub-scores on broader rating scales. Comparative evidence is lacking for this specific use, and controlled trial evidence isolating the effect independent of underlying conditions is scarce.

Uncertainty and Research Gaps in the Evidence

Key limitations exist where the research has not yet provided comprehensive answers. A primary gap is the limited information for long-term outcomes regarding the sustained patterns observed in relation to mood and overall functioning over several years. Data for certain groups, such as younger patients, remain insufficient. Research is ongoing, and future studies are needed to provide clearer insight into these areas.

Common questions about Desirel (FAQ)

---

Q: Is Desirel generally intended for short-term treatment or ongoing use?

Official documents describe the medicine as a treatment for Major Depressive Disorder (MDD), a condition for which ongoing treatment is commonly explored. Regulatory safety reviews of potential risks, such as suicidal thoughts, are noted to extend beyond the initial four months of treatment, which suggests the potential for long-term use.

Q: What are the recognized signs of a serious allergic reaction to Desirel?

While rare, official labeling indicates that signs of a serious hypersensitivity reaction may occur. These signs can include difficulty breathing, swelling of the face, lips, tongue, or throat, or a widespread rash and hives. Official labeling notes that these signs necessitate immediate medical evaluation.

Q: Are there any specific foods or drinks that should be avoided with Desirel?

Official regulatory guidance does not prohibit specific foods, but the guidance for use describes taking the medicine shortly after a meal or light snack to help minimize the risk of lightheadedness, dizziness, and stomach upset. Additionally, official documents caution against consuming alcohol because it can enhance the medicine's depressant effects on the central nervous system.

Q: Does taking Desirel with or without food change how the medicine is processed by the body?

Yes, official prescribing information indicates that taking the medicine with food can affect how it is processed (absorbed) by the body. The purpose for taking it with a meal is described as minimizing common adverse reactions like dizziness or stomach upset.

Q: Is the generic version of Desirel available and equivalent to the brand name?

The active component of Desirel is Trazodone Hydrochloride, which is widely available as a generic drug. Regulatory authorities require that generic versions meet the same quality and performance standards as the brand-name product.

Q: What does the term 'pharmacodynamics' mean in the context of Desirel?

Pharmacodynamics describes the drug's effects on the body. For Desirel, this involves altering chemical signaling in the brain, such as modulating serotonin activity by inhibiting its reuptake and blocking specific receptors. This action forms the basis of the drug’s therapeutic profile.

Q: What kind of monitoring might be suggested while taking Desirel?

Regulatory documents describe the need for close monitoring for any changes in mood, behavior, or the emergence of suicidal thoughts, especially during the first few months of use. Regulatory documents also require monitoring of blood levels for certain co-administered drugs like digoxin or phenytoin due to potential interaction risks.

Q: What is Desirel used for besides its primary indication?

According to the official regulatory documents, this medicine is formally indicated for the treatment of Major Depressive Disorder (MDD).

Q: How quickly does Desirel start to have an effect after the first dose?

Studies indicate that the medicine is absorbed relatively quickly. The time it takes for the immediate-release form to reach its maximum concentration in the blood (Tmax) is approximately one hour after taking it orally.

Q: What is the official information on weight gain as a side effect of Desirel?

Official regulatory reports from clinical trials indicate that weight gain was observed as an adverse reaction in a minority of outpatients (5%). Weight loss was also reported in other study participants.

Q: Are there any herbal supplements or vitamins that could interact with Desirel?

Yes, regulatory documents list specific herbal supplements that may interact with this medicine. The supplement St. John's wort is explicitly noted because co-administration can increase the risk of Serotonin Syndrome.

Q: What is the guidance on using common cold and flu medicines while taking Desirel?

Regulatory warnings suggest caution because many common cold and flu medicines contain ingredients that can interact. Combining this medicine with others that increase serotonin (like dextromethorphan) or cause central nervous system depression (like antihistamines) may increase the risk of serious side effects like Serotonin Syndrome or enhanced drowsiness.

Q: What is the general advice for a forgotten dose of Desirel?

The official patient counseling information describes taking a missed dose as soon as it is remembered. However, the guidance also states that if it is almost time for the next scheduled dose, the missed dose is to be skipped entirely to avoid doubling the amount taken.

Q: How long might it take to feel the full intended benefits of Desirel?

Studies and official information indicate that achieving the full intended benefits may require consistent use over several weeks. Official information indicates that the full effectiveness is often assessed after allowing up to six weeks of consistent use.

Q: How long does the active component of Desirel generally stay in a person's system?

Official pharmacokinetic data describes the elimination process in two phases. The initial phase, where the concentration drops rapidly, has a half-life of 3 to 6 hours, and the terminal phase has a half-life of 5 to 9 hours. This indicates the speed at which the active component is eliminated from the plasma.

Q: What is the general difference between a contraindication and a precaution for Desirel?

Regulatory documents define a contraindication as a condition under which the medicine must not be used due to a severe, prohibited risk. A precaution is a condition where the medicine can be used, but it requires caution, close monitoring, or specific risk-mitigation strategies.

Q: Has the FDA or other agencies issued any notable safety warnings about Desirel recently?

The official labeling includes a mandatory Boxed Warning that highlights the serious risk of Suicidal Thoughts and Behaviors, particularly in young adults. This is a key safety communication that the regulatory agency requires to be prominently displayed.

Q: Is Desirel classified as a controlled substance by regulatory bodies?

No, according to the official prescribing information, the drug is not classified as a controlled substance under the Controlled Substances Act by the U.S. regulatory body.

How to Store and Dispose of DESYREL®

DESYREL® (trazodone hydrochloride) tablets must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). Brief temperature excursions are permitted between 15 C and 30 C.

Storage Requirements

The medication must be dispensed and kept in a tight, light-resistant container, and the container must remain tightly closed. To ensure safety, DESYREL® must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired DESYREL® should be disposed of by following local pharmaceutical waste regulations or utilizing a drug take-back program when available. If take-back options are unavailable, the medicine must be prepared for disposal in household trash, which typically involves mixing it with an undesirable substance like used coffee grounds and sealing it in a container.